Search research articles
Contact Us
Filters
Showing results (41-50 of 65) with videos related to
Page
of 7
Sort By:
The Lancet. Microbe
|
October 13, 2023
Effect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trials
Emmanuel Musisi, Adam Wyness, Sahar Eldirdiri, et al.
The Journal of Infectious Diseases
|
March 27, 2012
Innovative trial designs are practical solutions for improving the treatment of tuberculosis
Patrick P J Phillips, Stephen H Gillespie, Martin Boeree, et al.
PLOS Digital Health
|
October 18, 2023
Developing contents for a digital adherence tool: A formative mixed-methods study among children and adolescents living with HIV in Tanzania
Iraseni Ufoo Swai, Lisa Lynn Ten Bergen, Alan Mtenga, et al.
Med (New York, N.Y.)
|
August 30, 2022
Interleukin-1 receptor antagonist anakinra as treatment for paradoxical responses in HIV-negative tuberculosis patients: A case series
Cynthia van Arkel, Martin Boeree, Cécile Magis-Escurra, et al.
Plos Medicine
|
November 21, 2023
Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis
Lufina Tsirizani Galileya, Roeland E Wasmann, Chishala Chabala, et al.
The Lancet. Diabetes & Endocrinology
|
September 8, 2014
Clinical management of concurrent diabetes and tuberculosis and the implications for patient services
Anca Lelia Riza, Fiona Pearson, Cesar Ugarte-Gil, et al.
Wellcome Open Research
|
September 4, 2018
High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study)
Fiona V Cresswell, Kenneth Ssebambulidde, Daniel Grint, et al.
AIDS and Behavior
|
September 22, 2025
The Acceptability of a Real-Time Medication Monitoring-Based Digital Adherence Tool Among Young People Living with HIV in Malawi
Takondwa Charles Msosa, Felix Phuka, Marion Sumari-de Boer, et al.
The Journal of Antimicrobial Chemotherapy
|
October 27, 2014
The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations
Ruth Bowness, Martin J Boeree, Rob Aarnoutse, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 21, 2022
Decreased Dolutegravir and Efavirenz Concentrations With Preserved Virological Suppression in Patients With Tuberculosis and Human Immunodeficiency Virus Receiving High-Dose Rifampicin
Christine Sekaggya-Wiltshire, Ruth Nabisere, Joseph Musaazi, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 65) with videos related to
Sort By:
Page
of 7
The Lancet. Microbe
|
October 13, 2023
Effect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trials
Emmanuel Musisi, Adam Wyness, Sahar Eldirdiri, et al.
The Journal of Infectious Diseases
|
March 27, 2012
Innovative trial designs are practical solutions for improving the treatment of tuberculosis
Patrick P J Phillips, Stephen H Gillespie, Martin Boeree, et al.
PLOS Digital Health
|
October 18, 2023
Developing contents for a digital adherence tool: A formative mixed-methods study among children and adolescents living with HIV in Tanzania
Iraseni Ufoo Swai, Lisa Lynn Ten Bergen, Alan Mtenga, et al.
Med (New York, N.Y.)
|
August 30, 2022
Interleukin-1 receptor antagonist anakinra as treatment for paradoxical responses in HIV-negative tuberculosis patients: A case series
Cynthia van Arkel, Martin Boeree, Cécile Magis-Escurra, et al.
Plos Medicine
|
November 21, 2023
Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis
Lufina Tsirizani Galileya, Roeland E Wasmann, Chishala Chabala, et al.
The Lancet. Diabetes & Endocrinology
|
September 8, 2014
Clinical management of concurrent diabetes and tuberculosis and the implications for patient services
Anca Lelia Riza, Fiona Pearson, Cesar Ugarte-Gil, et al.
Wellcome Open Research
|
September 4, 2018
High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study)
Fiona V Cresswell, Kenneth Ssebambulidde, Daniel Grint, et al.
AIDS and Behavior
|
September 22, 2025
The Acceptability of a Real-Time Medication Monitoring-Based Digital Adherence Tool Among Young People Living with HIV in Malawi
Takondwa Charles Msosa, Felix Phuka, Marion Sumari-de Boer, et al.
The Journal of Antimicrobial Chemotherapy
|
October 27, 2014
The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations
Ruth Bowness, Martin J Boeree, Rob Aarnoutse, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 21, 2022
Decreased Dolutegravir and Efavirenz Concentrations With Preserved Virological Suppression in Patients With Tuberculosis and Human Immunodeficiency Virus Receiving High-Dose Rifampicin
Christine Sekaggya-Wiltshire, Ruth Nabisere, Joseph Musaazi, et al.
Page
of 7